Which has better earnings and valuation, KALA or MDWD?

MediWound has higher revenue and earnings than KALA BIO. MediWound is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$96.14 N/A MediWound $14.48M 12.62 -$23.88M -$2.26 N/A

Is KALA or MDWD more profitable?

KALA BIO has a net margin of 0.00% compared to MediWound's net margin of -180.30%. MediWound's return on equity of -67.22% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% MediWound -180.30% -67.22% -31.87%

Which has better earnings and valuation, EQ or KALA?

Equillium has higher revenue and earnings than KALA BIO. Equillium is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Equillium $41.10M 4.32 -$22.40M -$0.32 N/A KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is EQ or KALA more profitable?

Equillium's return on equity of -61.43% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -61.43% -53.72% KALA BIO N/A -1,336.10% -94.85%

Do analysts recommend TLSA or KALA?

KALA BIO has a consensus target price of $1,018.75, indicating a potential upside of 38,635.74%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts clearly believe KALA BIO is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, TLSA or KALA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is TLSA or KALA more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A KALA BIO N/A -1,336.10% -94.85%

Is TNYA or KALA more profitable?

Tenaya Therapeutics' return on equity of -80.56% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -80.56% -65.21% KALA BIO N/A -1,336.10% -94.85%

Which has better earnings and valuation, KALA or ABOS?

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$96.14 N/A Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A

Is KALA or ABOS more profitable?

Acumen Pharmaceuticals' return on equity of -123.07% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% Acumen Pharmaceuticals N/A -123.07% -79.41%

KALA BIO (KALA) Competitors

$2.63 +0.16 (+6.48%)

Closing price 04:00 PM Eastern

Extended Trading

$2.60 -0.03 (-1.10%)

As of 07:59 PM Eastern

Compare

KALA vs. MDWD, EQ, TLSA, TNYA, and ABOS

Should you buy KALA BIO stock or one of its competitors? MarketBeat compares KALA BIO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with KALA BIO include MediWound (MDWD), Equillium (EQ), Tiziana Life Sciences (TLSA), Tenaya Therapeutics (TNYA), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "pharmaceutical products" industry.

How does KALA BIO compare to MediWound?

KALA BIO (NASDAQ:KALA) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

KALA BIO has a net margin of 0.00% compared to MediWound's net margin of -180.30%. MediWound's return on equity of -67.22% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
MediWound	-180.30%	-67.22%	-31.87%

KALA BIO currently has a consensus price target of $1,018.75, indicating a potential upside of 38,635.74%. MediWound has a consensus price target of $34.00, indicating a potential upside of 139.10%. Given KALA BIO's higher possible upside, research analysts plainly believe KALA BIO is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, KALA BIO had 1 more articles in the media than MediWound. MarketBeat recorded 2 mentions for KALA BIO and 1 mentions for MediWound. KALA BIO's average media sentiment score of 0.44 beat MediWound's score of -0.22 indicating that KALA BIO is being referred to more favorably in the media.

Company	Overall Sentiment
KALA BIO	Neutral
MediWound	Neutral

MediWound has higher revenue and earnings than KALA BIO. MediWound is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
MediWound	$14.48M	12.62	-$23.88M	-$2.26	N/A

24.6% of KALA BIO shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 2.2% of KALA BIO shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

KALA BIO has a beta of -2.4, indicating that its stock price is 340% less volatile than the broader market. Comparatively, MediWound has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market.

Summary

MediWound beats KALA BIO on 10 of the 15 factors compared between the two stocks.

How does KALA BIO compare to Equillium?

Equillium (NASDAQ:EQ) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Equillium currently has a consensus target price of $7.57, indicating a potential upside of 169.45%. KALA BIO has a consensus target price of $1,018.75, indicating a potential upside of 38,635.74%. Given KALA BIO's higher probable upside, analysts clearly believe KALA BIO is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Equillium has higher revenue and earnings than KALA BIO. Equillium is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	4.32	-$22.40M	-$0.32	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

27.1% of Equillium shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 17.8% of Equillium shares are owned by insiders. Comparatively, 2.2% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Equillium's return on equity of -61.43% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
KALA BIO	N/A	-1,336.10%	-94.85%

Equillium has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.4, indicating that its stock price is 340% less volatile than the broader market.

In the previous week, Equillium had 2 more articles in the media than KALA BIO. MarketBeat recorded 4 mentions for Equillium and 2 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.44 beat Equillium's score of 0.06 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Overall Sentiment
Equillium	Neutral
KALA BIO	Neutral

Summary

Equillium beats KALA BIO on 12 of the 15 factors compared between the two stocks.

How does KALA BIO compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Tiziana Life Sciences' return on equity of 0.00% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
KALA BIO	N/A	-1,336.10%	-94.85%

Tiziana Life Sciences has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.4, indicating that its stock price is 340% less volatile than the broader market.

In the previous week, KALA BIO had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 2 mentions for KALA BIO and 1 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.87 beat KALA BIO's score of 0.44 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Tiziana Life Sciences	Very Positive
KALA BIO	Neutral

KALA BIO has a consensus target price of $1,018.75, indicating a potential upside of 38,635.74%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts clearly believe KALA BIO is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

24.6% of KALA BIO shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by company insiders. Comparatively, 2.2% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Tiziana Life Sciences beats KALA BIO on 6 of the 11 factors compared between the two stocks.

How does KALA BIO compare to Tenaya Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

KALA BIO has lower revenue, but higher earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	$225K	686.49	-$90.60M	-$0.47	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

Tenaya Therapeutics has a beta of 2.82, suggesting that its stock price is 182% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.4, suggesting that its stock price is 340% less volatile than the broader market.

Tenaya Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 461.96%. KALA BIO has a consensus price target of $1,018.75, suggesting a potential upside of 38,635.74%. Given KALA BIO's higher possible upside, analysts clearly believe KALA BIO is more favorable than Tenaya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by insiders. Comparatively, 2.2% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tenaya Therapeutics' return on equity of -80.56% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
KALA BIO	N/A	-1,336.10%	-94.85%

In the previous week, Tenaya Therapeutics and Tenaya Therapeutics both had 2 articles in the media. Tenaya Therapeutics' average media sentiment score of 0.50 beat KALA BIO's score of 0.44 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tenaya Therapeutics	Neutral
KALA BIO	Neutral

Summary

Tenaya Therapeutics beats KALA BIO on 11 of the 14 factors compared between the two stocks.

How does KALA BIO compare to Acumen Pharmaceuticals?

KALA BIO (NASDAQ:KALA) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than KALA BIO. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 2 mentions for KALA BIO. Acumen Pharmaceuticals' average media sentiment score of 0.67 beat KALA BIO's score of 0.44 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
KALA BIO	Neutral
Acumen Pharmaceuticals	Positive

Acumen Pharmaceuticals' return on equity of -123.07% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

KALA BIO has a beta of -2.4, suggesting that its share price is 340% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

KALA BIO presently has a consensus target price of $1,018.75, indicating a potential upside of 38,635.74%. Acumen Pharmaceuticals has a consensus target price of $6.67, indicating a potential upside of 181.29%. Given KALA BIO's higher probable upside, analysts clearly believe KALA BIO is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Acumen Pharmaceuticals beats KALA BIO on 10 of the 13 factors compared between the two stocks.

Get KALA BIO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KALA vs. The Competition

Export

Metric	KALA BIO	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$48.89M	$3.37B	$6.49B	$11.98B
Dividend Yield	N/A	2.32%	2.67%	5.57%
P/E Ratio	-0.03	19.65	23.85	24.45
Price / Sales	N/A	312.51	572.24	136.74
Price / Cash	N/A	120.36	43.20	54.62
Price / Book	0.21	8.32	10.66	6.80
Net Income	-$26.98M	$23.89M	$3.56B	$337.76M
7 Day Performance	27.67%	0.94%	0.05%	2.08%
1 Month Performance	-15.71%	-1.16%	0.37%	3.16%
1 Year Performance	-98.82%	41.51%	22.73%	27.78%

KALA BIO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KALA KALA BIO	2.1698 of 5 stars	$2.63 +6.5%	$1,018.75 +38,635.7%	-98.9%	$45.92M	N/A	N/A	30	Short Interest Increase High Trading Volume
MDWD MediWound	2.8613 of 5 stars	$13.74 -0.1%	$34.00 +147.4%	-31.5%	$176.85M	$16.96M	N/A	80
EQ Equillium	2.7627 of 5 stars	$3.11 +11.5%	$7.57 +143.5%	+633.4%	$176.40M	$41.10M	N/A	40	High Trading Volume
TLSA Tiziana Life Sciences	1.0411 of 5 stars	$1.18 -13.2%	N/A	-22.6%	$173.07M	N/A	N/A	8	Positive News Upcoming Earnings High Trading Volume
TNYA Tenaya Therapeutics	2.1531 of 5 stars	$0.79 -0.5%	$4.00 +409.0%	+13.9%	$171.43M	N/A	N/A	110	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KALA) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

KALA BIO (KALA) Competitors

KALA vs. MDWD, EQ, TLSA, TNYA, and ABOS

How does KALA BIO compare to MediWound?

Summary

How does KALA BIO compare to Equillium?

Summary

How does KALA BIO compare to Tiziana Life Sciences?

Summary

How does KALA BIO compare to Tenaya Therapeutics?

Summary

How does KALA BIO compare to Acumen Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALA vs. The Competition

KALA BIO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

KALA BIO (KALA) Competitors

KALA vs. MDWD, EQ, TLSA, TNYA, and ABOS

How does KALA BIO compare to MediWound?

Is KALA or MDWD more profitable?

Do analysts rate KALA or MDWD?

Does the media prefer KALA or MDWD?

Which has better earnings and valuation, KALA or MDWD?

Do insiders & institutionals hold more shares of KALA or MDWD?

Which has more volatility & risk, KALA or MDWD?

Summary

How does KALA BIO compare to Equillium?

Do analysts rate EQ or KALA?

Which has better earnings and valuation, EQ or KALA?

Do institutionals and insiders believe in EQ or KALA?

Is EQ or KALA more profitable?

Which has more volatility and risk, EQ or KALA?

Does the media favor EQ or KALA?

Summary

How does KALA BIO compare to Tiziana Life Sciences?

Is TLSA or KALA more profitable?

Which has more risk and volatility, TLSA or KALA?

Does the media favor TLSA or KALA?

Do analysts recommend TLSA or KALA?

Which has better valuation and earnings, TLSA or KALA?

Do institutionals and insiders believe in TLSA or KALA?

Summary

How does KALA BIO compare to Tenaya Therapeutics?

Which has preferable earnings & valuation, TNYA or KALA?

Which has more volatility & risk, TNYA or KALA?

Do analysts rate TNYA or KALA?

Do insiders and institutionals believe in TNYA or KALA?

Is TNYA or KALA more profitable?

Does the media favor TNYA or KALA?

Summary

How does KALA BIO compare to Acumen Pharmaceuticals?

Which has better earnings and valuation, KALA or ABOS?

Does the media refer more to KALA or ABOS?

Is KALA or ABOS more profitable?

Do insiders and institutionals believe in KALA or ABOS?

Which has more volatility and risk, KALA or ABOS?

Do analysts recommend KALA or ABOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALA vs. The Competition

KALA BIO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools